Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
نویسندگان
چکیده
Abstract Background Afatinib has shown favorable response rates (RRs) and longer progression free survival (PFS) in lung cancer patients harboring EGFR mutations compared with standard platinum-based chemotherapy. However, serious adverse drug reactions (ADRs) limit the clinical application of afatinib. Methods We designed a retrospective study, enrolling all metastatic adenocarcinoma who were diagnosed treated 30 or 40 mg daily afatinib as their initial treatment three Kaohsiung Medical University-affiliated hospitals Taiwan. Results A total 179 enrolled which 102 (57%) 77 (43%) received treatment, respectively. The initially using had similar RR (75% vs. 83%, p = 0.1672), median PFS (14.5 14.8 months, log-rank 0.4649), OS (34.0 25.2 0.5982) those daily. Patients receiving fewer ADRs overall incidence moderate severe was significantly lower (49% 77%, 0.002 ); findings observed terms (7% 24%, < 0.0001 ). Conclusion RR, PFS, OS, but ADRs, starting dose.
منابع مشابه
Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations
Background: Although superior clinical benefits of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer (NSCLC) had been reported with different sensitivity, the sensitivity of second-line TKIs in NSCLC patients with different EFGR mutations was unknown. The purpose of this study is to investigate the clinic...
متن کاملMicroRNA Signature of Lung Adenocarcinoma with EGFR Exon 19 Deletion
The findings of EGFR mutations and the development of targeted therapies have significantly improved the overall survival of lung cancer patients. Still, the prognosis remains poor, so we need to know more about the genetic alterations in lung cancer. MicroRNAs are dysregulated in lung cancer, and some of them can regulate EGFR. So it is very important to predict the candidate microRNAs that ta...
متن کاملEGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
PURPOSE Epidermal growth factor receptor (EGFR) genotyping is now standard in the management of advanced lung adenocarcinoma, as this biomarker predicts marked benefit from treatment with EGFR tyrosine kinase inhibitors (TKI). EGFR exon 19 insertions are a poorly described family of EGFR mutations, and their association with EGFR-TKI sensitivity in lung adenocarcinoma is uncertain. EXPERIMENT...
متن کاملAfatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.
BACKGROUND A recent pooled analysis of the LUX-LUNG3 and LUX-LUNG6 trials suggested that afatinib (an irreversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)) is especially effective against non-small cell lung cancer (NSCLC) carrying an EGFR exon 19 deletion. MATERIALS AND METHODS Stable viral transfectant HEK293 cell lines carrying an exon 19 deletion (HEK293/19 d...
متن کاملU.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva, Astellas Pharma Inc., Northbrook, IL, http://www.us.astellas.com/) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. This indication for erlotinib was a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMC Cancer
سال: 2021
ISSN: ['1471-2407']
DOI: https://doi.org/10.1186/s12885-021-08235-3